Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019

SMi Group8 - 9 April 2019, Boston, USA.
The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

In the run up to the conference, SMi Group caught up with Patrick Gallagher, Business Development Manager, SCHOTT Pharmaceutical Systems, to discuss his upcoming presentation, and his thoughts on the current challenges and opportunities in the pre-filled syringes field.

A snapshot of Patrick Gallagher's interview

Q: The Pre-Filled Syringes market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments? A: "In recent years, we have seen quite a bit of interest from pharmaceutical companies to differentiate through delivery device, whether through lifecycle management of a biologic drug into a more complex device or by converting a legacy drug from vial to pre-filled syringe. PFS and cartridge-based primary containers can improve patient safety through less dose preparation and greater ease of use, as well as facilitate the transition of drug administration from a hospital to homecare setting, thus improving patient outcomes."

Q: What do you see as the greatest challenge for you to overcome personally in the pre-filled syringes field at the moment? A: "As an industry, we are still in the early stages of developing connected health solutions and while we are starting to generate significant data it will take some time to best realize how to use this data. Pharma and Medtech companies will need to continue to educate key healthcare stakeholders that device-generated data can improve patient outcomes and drive down healthcare costs."

The full speaker interview and more content including the latest brochure, past attendees list, and other exclusive speaker interviews can be found on the DOWNLOADS section on the website at http://www.pfsamericas.com/pr7

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...